What does NL PHARMA do?

NL PHARMA is a pharmacy in Florennes. Private Limited, started on 1 September 2016, 1 establishment.

What is the address of NL PHARMA?

The registered office of NL PHARMA is located at Allée des Fougères, Morialmé 412, 5620 Florennes.

Is NL PHARMA still active?

Yes. According to the CBE (31 October 2026) NL PHARMA is active, legal situation “Normale toestand”, started on 1 September 2016.

Is NL PHARMA registered on Peppol?

Yes, NL PHARMA is registered on the Peppol network with ID 0208:0661907808.

What is the enterprise number of NL PHARMA?

The enterprise number of NL PHARMA is BE0661907808.

When was NL PHARMA founded?

NL PHARMA was founded on 1 September 2016.

Who are the directors of NL PHARMA?

According to the 2025 annual accounts, the directors of NL PHARMA are: Nicolas LESTARQUY.

Is NL PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 September 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did NL PHARMA make in 2025?

NL PHARMA recorded a loss after taxes of € 1,457 in financial year 2025.

What is the revenue of NL PHARMA?

As a small company, NL PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 7,229.

NL PHARMA (Private Limited) - Florennes - BE0661907808

Dossier NL PHARMA, printed on 1 November 2026 from databakkes.be/en/0661907808/nl-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

NL PHARMA from Florennes, company number BE0661907808, closed financial year 2025 with a result of € -1,457 after tax. For that financial year NL PHARMA recorded a gross margin of € 7,229 and equity of € 4,488. Compared with financial year 2024, the result moved from € 4,242 to € -1,457. The company made a loss. The buffer shrank hard: equity is 85 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.

What it is worth Shrank hard

€ 4,488

▼ 85% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1,457

▼ still € 4,242 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 107

▲ 272% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -1,712.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 89

▼ 74% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 12,210

▲ 101% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 6,060

▼ 80% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 40,300 Gross margin 2022: € 40,300 First fiscal year in the series	€ 20,869 Gross margin 2023: € 20,869 ▼ 48% vs 2022 (€ 40,300) Unfavourable step	€ 20,551 Gross margin 2024: € 20,551 ▼ 2% vs 2023 (€ 20,869) Unfavourable step	€ 7,229 Gross margin 2025: € 7,229 ▼ 65% vs 2024 (€ 20,551) Unfavourable step	▼ 65%
Profit after taxes	€ 16,694 Profit after taxes 2022: € 16,694 First fiscal year in the series	€ -5,763 Profit after taxes 2023: € -5,763 ▼ € 22,457 vs 2022 (€ 16,694) Unfavourable step	€ 4,242 Profit after taxes 2024: € 4,242 ▲ € 10,004 vs 2023 (€ -5,763) Favourable step	€ -1,457 Profit after taxes 2025: € -1,457 ▼ € 5,698 vs 2024 (€ 4,242) Unfavourable step	▼ € 5,698
Equity	€ 46,819 Equity 2022: € 46,819 First fiscal year in the series	€ 31,758 Equity 2023: € 31,758 ▼ 32% vs 2022 (€ 46,819) Unfavourable step	€ 30,363 Equity 2024: € 30,363 ▼ 4% vs 2023 (€ 31,758) Unfavourable step	€ 4,488 Equity 2025: € 4,488 ▼ 85% vs 2024 (€ 30,363) Unfavourable step	▼ 85%
Total debts	€ 39,135 Total debts 2022: € 39,135 First fiscal year in the series	€ 51,968 Total debts 2023: € 51,968 ▲ 33% vs 2022 (€ 39,135) Unfavourable step	€ 47,889 Total debts 2024: € 47,889 ▼ 8% vs 2023 (€ 51,968) Favourable step	€ 29,270 Total debts 2025: € 29,270 ▼ 39% vs 2024 (€ 47,889) Favourable step	▼ 39%
Cash	€ 3,719 Cash 2022: € 3,719 First fiscal year in the series	€ 3,881 Cash 2023: € 3,881 ▲ 4% vs 2022 (€ 3,719) Favourable step	€ 29 Cash 2024: € 29 ▼ 99% vs 2023 (€ 3,881) Unfavourable step	€ 107 Cash 2025: € 107 ▲ 272% vs 2024 (€ 29) Favourable step	▲ 272%
Retained profit	€ 40,619 Retained profit 2022: € 40,619 First fiscal year in the series	€ 25,558 Retained profit 2023: € 25,558 ▼ 37% vs 2022 (€ 40,619) Unfavourable step	€ 24,163 Retained profit 2024: € 24,163 ▼ 5% vs 2023 (€ 25,558) Unfavourable step	€ -1,712 Retained profit 2025: € -1,712 ▼ € 25,875 vs 2024 (€ 24,163) Unfavourable step	▼ € 25,875
Dividend	€ 9,118 Dividend 2022: € 9,118 First fiscal year in the series	€ 9,298 Dividend 2023: € 9,298 ▲ 2% vs 2022 (€ 9,118) Unchanged	€ 5,636 Dividend 2024: € 5,636 ▼ 39% vs 2023 (€ 9,298) Unchanged	€ 24,418 Dividend 2025: € 24,418 ▲ € 18,782 vs 2024 (€ 5,636) Unchanged	▲ € 18,782
Bank debt	€ 12,649 Bank debt 2022: € 12,649 First fiscal year in the series	€ 4,739 Bank debt 2023: € 4,739 ▼ 63% vs 2022 (€ 12,649) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 4,739) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 85,953 Balance sheet total 2022: € 85,953 First fiscal year in the series	€ 83,726 Balance sheet total 2023: € 83,726 ▼ 3% vs 2022 (€ 85,953) Unchanged	€ 78,252 Balance sheet total 2024: € 78,252 ▼ 7% vs 2023 (€ 83,726) Unchanged	€ 33,758 Balance sheet total 2025: € 33,758 ▼ 57% vs 2024 (€ 78,252) Unchanged	▼ 57%

Key figures of NL PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to NL PHARMA?

What happened at NL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 24, 2026 New annual accounts for financial year 2025: loss of € 1,457 (▼ € 5,698 vs 2024). filed late Source: NBB ↗
Oct 1, 2016 New establishment in Florennes. KBO
2016 Nicolas LESTARQUY became a director. NBB
Sep 1, 2016 Start of the company according to the CBE. KBO

In short

From € 16,694 profit in 2022 to € 1,457 loss in 2025.

Paid € 15,257 in corporate taxes since 2022.

Best year ever: 2022, with € 16,694 profit.

Paid out € 48,471 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Nicolas LESTARQUY

NL PHARMA

Behind NL PHARMA is Nicolas LESTARQUY.

Directors

According to the 2025 annual accounts

Nicolas LESTARQUY

Director

since 2016

Establishments

Establishment units

Physical locations of this company

Registered office

Allée des Fougères, Morialmé 412

5620 Florennes

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0661.907.808
VAT number: BE 0661.907.808
Registered office: Allée des Fougères, Morialmé 412, 5620 Florennes
Names & denominations: NL PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 1 September 2016
Peppol: Active · Active since 1 Jan 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗